Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Marching into the second decade after the approval of ipilimumab, it is clear that immune
checkpoint inhibitors (ICIs) have dramatically improved the prognosis of melanoma …

Background Immune checkpoint inhibitors had a great effect in triple-negative breast cancer
(TNBC); however, they benefited only a subset of patients, underscoring the need to co …

Summary LAG-3, TIM-3, and TIGIT comprise the next generation of immune checkpoint
receptors being harnessed in the clinic. Although initially studied for their roles in restraining …

Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1
(PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with …

Anti–PD-1/PD-L1 therapy, either by anti–PD-1 antibody or anti–PD-L1 antibody, has efficacy
by reinvigorating tumor-infiltrating CD8+ T cells in a subset of patients with cancer, but it has …

Melanoma is one of the seven most common cancers in the United States, and its incidence
is still increasing. Since 2011, developments in targeted therapies and immunotherapies …

Background The widespread use of Immune checkpoint-inhibitors (ICI) has revolutionised
treatment of multiple cancer types. However, selecting patients who may benefit from ICI …

Simple Summary Although the incorporation of immune checkpoint inhibitors (ICIs) in
melanoma treatment has significantly improved prognosis for patients with advanced …

Resistance to immune checkpoint inhibitors (ICIs) is a major issue of the current era in
cancer immunotherapy. Immune evasion is a multi-factorial event, which occurs generally at …